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Functional interpretation of genomic variation is critical to understanding human disease, but it remains difficult to predict the effects of specific mutations on protein interaction networks and the phenotypes they regulate. We describe an analytical framework based on multiscale statistical mechanics that integrates genomic and biophysical data to model the human SH2-phosphoprotein network in normal and cancer cells. We apply our approach to data in The Cancer Genome Atlas (TCGA) and test model predictions experimentally. We find that mutations mapping to phosphoproteins often create new interactions but that mutations altering SH2 domains result almost exclusively in loss of interactions. Some of these mutations eliminate all interactions, but many cause more selective loss, thereby rewiring specific edges in highly connected subnetworks. Moreover, idiosyncratic mutations appear to be as functionally consequential as recurrent mutations. By synthesizing genomic, structural and biochemical data, our framework represents a new approach to the interpretation of genetic variation.
TCGA and similar projects have generated extensive data on the mutational landscape of tumors 1 . To understand the functional consequences of these mutations, it is necessary to ascertain how they alter the protein-protein interaction (PPI) networks involved in regulating cellular phenotypes. A wide spectrum of data are available on PPIs, ranging from large-scale binding experiments [2] [3] [4] to co-crystal studies. The interpretation of such data is hampered by the absence of an analytical framework for integrating diverse measurements and for modeling the effects of cancer mutations. Such a framework must jointly model the genetic heterogeneity of cancer and the biophysical determinants of PPI specificity at the level of individual protein domains, multidomain proteins and PPI networks. In this report, we describe such a multiscale statistical mechanical (MSM) framework focusing on the subset of PPIs involving protein interaction domains (PIDs) in which SH2 domains bind to phosphotyrosine peptides. Such interactions are essential components of receptor-mediated signaling, and their misregulation is known to have a role in cancer and other diseases [5] [6] [7] [8] .
The first challenge in modeling PID networks is integrating data from diverse low-throughput and high-throughput assays.
Low-throughput methods such as fluorescence polarization spectroscopy provide precise interaction data on a few dozen PIDs and ligands but cannot easily be scaled to the full proteome 2 , whereas high-throughput array-based methods provide greater scale but suffer from systematic artifacts and high false positive and false negative rates, resulting in data sets that only partly agree 2 . An additional challenge is modeling the effects of mutations for proteins with multiple binding domains and/or multiple sites of phosphorylation 9 , a reality for most signaling proteins (for example, the CRK oncoprotein). Existing methods are either limited to individual domains [10] [11] [12] [13] or are insufficiently precise to discern the effects of singleresidue changes 14, 15 .
The MSM framework we have developed combines genomic, binding and structural data and reconciles inconsistencies within and among data sets to generate PID networks for normal and cancer cells. We develop a bottom-up first-principles approach, involving a single mathematical equation based on statistical mechanical ensembles, that models domains, proteins and networks, and we then apply this approach to the analysis of SH2 networks and mutations found in TCGA 16 . We validate newly predicted interactions experimentally and demonstrate the sensitivity of MSM to single-residue mutations that cause subtle changes in binding affinity. Our analysis provides mechanistic insights into an important PID cancer network and validates a computational approach to PID networks that can be applied to other signaling domains and other diseases. t e c h n i c a l r e p o r t s as a machine learning problem and develop a reverse workflow in which measurements of thermodynamic quantities are used to derive a Hamiltonian for SH2 domain and phosphotyrosine peptide interactions 17 (Fig. 1c) . Notably, statistical mechanics does not fully constrain the mathematical form of the Hamiltonian or the set of states-known as the ensemble-whose thermodynamic properties are being computed. We exploit this fact by choosing a form for the Hamiltonian that can model arbitrary SH2-peptide interactions, including for mutated domains and unknown phosphotyrosine peptides. This Hamiltonian is defined in terms of interactions between one residue in the peptide and one residue in the SH2 domain, ignoring multi-residue interactions and steric effects between residues in the same protein. Thus, it is more appropriately termed a pseudo-Hamiltonian.
We also exploited freedom in selecting ensembles. When the pseudo-Hamiltonian is learned, an ensemble comprises the bound and unbound states of an SH2 domain and a single phosphotyrosine peptide ( Fig. 1d) . Such domain-level ensembles correspond to readily available thermodynamic measurements, and we can therefore use a wide variety of low-and high-throughput data in inferring the pseudo-Hamiltonian (for a mathematical treatment, see the Supplementary Note and Supplementary  Figs. 1 and 2) . Subsequently, we used the pseudo-Hamiltonian to compute difficult-to-obtain thermodynamic quantities for ensembles of multidomain proteins and multiply phosphorylated substrates ( Fig. 1e) . In principle, data on isolated domains, multidomain proteins and multiply phosphorylated substrates can be used in learning. In practice, virtually all experimental data relate to single domain-phosphotyrosine peptide interactions. Thus, ensemble theory allows us to circumvent limitations in available data to predict interactions involving the types of proteins that are actually found in signaling networks.
To perform learning, we combined binding data from four highthroughput data sets [18] [19] [20] [21] ('MacBeath' , 'Jones' , 'Nash' and 'Cesareni') and a diverse set of low-throughput data 21 ( Supplementary Table 1 ). The combined data set spanned 111 SH2 domains (out of 122 known; no data were available for 11 domains) and 5,016 phosphotyrosine peptide sequences (the human proteome is estimated to contain ~37,000 phosphotyrosine sites lying in ~12,000 proteins 22 ). Data were binarized, yielding a training set of ~20,000 positive and ~400,000 negative interactions. From this training set, we learned the residue-residue energies of the pseudo-Hamiltonian by maximizing the agreement between the predicted and experimental affinities of domains. We also aligned SH2 domains with 25 SH2-peptide co-crystal structures and exploited the resulting spatial information by applying the wellestablished principle 23 that selectivity is primarily determined by interacting residues in direct physical contact. Mathematically, this principle was imposed by penalizing energy terms in proportion to the distance separating residues, thereby assigning weaker energies to more distant interactions.
Domain model achieves high accuracy and reconciles data sets
We evaluated the performance of the MSM domain model (MSM/D) using a nested cross-validation approach designed to prevent overfitting. Data were randomly divided into three parts: one for fitting residue interaction energies, one for fitting distance-dependent energy penalization and one for model tests (Supplementary Fig. 3a) . We compared MSM/D to two existing SH2 models (SMALI 10 and PEPINT 11 ) and to a general PPI method, PrePPI 14 , using a receiver operator characteristic (ROC) curve ( Fig. 2a) . Global and data setspecific performance was evaluated by grouping high-throughput data into four subsets on the basis of their source. We also subdivided data by combining the low-throughput data set with high-confidence interactions (i.e., those confirmed by two (HC2) and three (HC3) data sources). Data for high-confidence interactions were removed from the high-throughput data sets to prevent cross-contamination during training.
We observed that MSM/D substantially outperformed existing methods in the 'high-precision' regime (false positive rate (FPR) = 0.001), yielding a true positive rate (TPR) that was 6 times higher than that for the best existing method across all data and >50 times higher for the HC2 subset ( Fig. 2a) . Integrating the area under the ROC curve (AUC) yields a single performance number, and this too was substantially higher for MSM/D than existing models on all subsets of the data ( Table 1) . Relative performance was particularly high for 'gold standard' subsets, with MSM/D achieving a nearly perfect score of 0.99 AUC on the HC3 data set. The superiority of MSM/D relative to PrePPI does not take into account the latter's ability to model any protein; we include the comparison only to establish a baseline for general PPI methods. In addition, SMALI and PEPINT were trained on data sets only about onethird as large as that used for MSM/D; we therefore retrained MSM/D Fig. 3e ) and found that the retrained model attained ~97% of the maximum AUC, which remained substantially superior to the SMALI and PEPINT approaches. We also computed separate ROC and metaparameter sensitivity curves for each cross-validation set ( Supplementary  Fig. 3b,c) . The curves overlapped almost perfectly, indicating that MSM/D is robust to variation in training data. We conclude that MSM/D is substantially better than available methods at modeling interactions between SH2 domains and phosphotyrosine peptides. Available data sets for SH2-peptide interaction only partially agree 2, 4, 24 , likely owing to systematic biases and high numbers of false negative and false positive errors. We therefore tested the ability of MSM/D to reconcile disagreement in the experimental record. FPR and TPR were estimated for three high-throughput assays ( Fig. 2b) through comparison with HC3 data. We found that, at all FPR levels, MSM/D exhibited higher precision and recall than any experimental data set. To test the ability of MSM/D to integrate diverse data, we left out one of the five data sets during training and then tested the model against the excluded data set. MSM/D performance remained high against highconfidence data sets (for example, AUC of 0.938 versus 0.947 on HC2) but dropped when predictions were tested on the high-throughput data set excluded during training ( Table 2) . We interpret this decrease as arising from systematic error in the excluded data that cannot be modeled a priori; however, we cannot exclude impact from the uneven coverage of sequence space. Our results nonetheless show that MSM/D can correct for random and systematic experimental errors to generate a consolidated representation of SH2-phosphotyrosine interactions that is superior to any single data set or simple polling strategies.
To determine the ability of MSM/D to model SH2 domains absent from the training set, we retrained the model on data from which one domain had been excluded and then computed the AUC for the excluded domain; the process was iterated over all SH2 domains. In Figure 2c , we plot AUCs as a function of the sequence identity between the excluded domain and its nearest included neighbor. MSM/D modeled excluded SH2 domains with an AUC of ~0.8, even when sequence identity to the nearest neighbor averaged ~62%. In contrast, prediction of unknown domains cannot be performed using PEPINT and SMALI. When we left out ~13 SH2 domains at a time, reducing nearest neighbor sequence identity to ~45% ( Supplementary  Fig. 3d ), the AUC dropped to ~0.75, but the model retained substantial predictive capability. We also examined the properties of the 11 SH2 domains for which no experimental data were available and found binding selectivity comparable to that of other SH2 domains but ~50-fold fewer binding partners (at a threshold of P > 0.85). Thus, the absence of data for these 11 domains likely reflects the low probability of observing an interaction experimentally 18 . We conclude that MSM/D can model unseen SH2 domains and peptides, including those altered by cancer mutations.
Protein and mutation models capture multi-site interactions
Interactions between SH2-and phosphotyrosine-containing proteins involve tandem domains and phosphoproteins with up to 25 phosphosites. A majority (82/112) of SH2-containing proteins also contain one or more phosphotyrosine sites. To model such interactions, we constructed statistical mechanical ensembles comprising all physical binding configurations, accounting for the combinatorics of multiple domains and phosphosites ( Fig. 1e and Supplementary  Fig. 1) , to yield the MSM protein model (MSM/P). Competitive binding between sites is accounted for by the ensemble formulation. By default, MSM/P assumes that all phosphosites are phosphorylated and interacting proteins are equally expressed, but this assumption is unlikely to pertain to actual cells and can be relaxed.
To validate MSM/P experimentally, we focused on GCSAM, a protein previously implicated in B cell lymphoma 25, 26 for which a large discrepancy exists between the number of published interacting SH2 partners (two are known: GRB2 (ref. 27 ) and SYK 28 ) and the number predicted by MSM/P (nine more are predicted with affinities comparable to that of GRB2). We coexpressed GCSAM fused to the monomeric red fluorescent protein TagRFP and 1 of 12 SH2 domains tagged with GFP. HEK293T cells were then treated with pervanadate for 5 min to promote tyrosine phosphorylation, lysates were prepared and SH2-containing complexes were immunoprecipitated using anti-GFP beads. Fluorescent imaging of the beads and the supernatant made it possible to normalize the level of bound SH2 domain to the total levels of SH2 and GCSAM expression, resulting in excellent reproducibility between biological replicates (ρ = 0.99; Fig. 3a ). Using the bead-based assay, we detected binding by all SH2 domains predicted by MSM/P to associate with GCSAM, and the correlation npg t e c h n i c a l r e p o r t s between measured and predicted affinities was high (ρ = 0.80; Fig. 3a ). This is a stringent test of MSM/P as (i) the evaluation of agreement is quantitative and spans a broad range of affinities, (ii) the SH2 domains we tested had diverse primary sequences and (iii) GCSAM contains three phosphotyrosine sites, thereby testing the performance of the protein-level ensemble model. Next, we modeled the effects of mutations on SH2-phosphotyrosine interactions by constructing ensembles whose states simultaneously represented the behavior of the PPI before and after mutation ( Fig. 1e and Supplementary Fig. 1 ). The resulting model distinguishes between consequential and non-consequential changes in binding affinity (Supplementary Fig. 2) and accounts for the 'protein context' of a mutation, including buffering effects from other phosphosites or domains present in the same protein. To experimentally evaluate the sensitivity of MSM/P to single-amino-acid substitutions, we analyzed binding of the regulatory α subunit of phosphatidylinositol 3-kinase, PIK3R1, to a mutant of the insulin-like growth factor receptor, IGF1R Ala1347Val (COSM12856; encoded by a mutation in squamous cell carcinoma 29 ). This represents a stringent test of the model because (i) it does not create a predictable canonical motif such as pYXXM (where pY represents the phosphotyrosine); (ii) the mutation occurs in the complex protein context of IGF1R, which has 11 phosphosites 22 ; (iii) we predict a gain-of-function increase in affinity rather than a more common loss-of-function decrease; and (iv) PIK3R1 contains 2 SH2 domains. We coexpressed GFPtagged IGF1R with a construct for mCherry linked to either the N-or C-terminal PIK3R1 SH2 domain or a construct encoding both domains and performed quantitative coimmunoprecipitation using anti-RFP beads. As predicted, IGF1R Ala1347Val exhibited stronger binding to the SH2 domains of PIK3R1 than the wild-type protein (one-sided t test for five biological replicates of P = 6.2 × 10 −5 for the N-terminal domain, P = 9.0 × 10 −3 for the C-terminal domain and P = 5.9 × 10 −5 for the tandem protein; Fig. 3b ). The increase in affinity was correctly predicted to stem from stronger binding of both domains to mutant receptor, with the C-terminal domain being the stronger of the two (P = 0.016). The effect is potentially biologically relevant, as PIK3R1 and IGF1R are oncoproteins that interact through the adaptor IRS1. We conclude that MSM/P is effective at capturing the effects of mutations on SH2-phosphotyrosine binding affinity. However, the npg t e c h n i c a l r e p o r t s data also highlight the limitation that MSM/P does not account for non-additive avidity effects in tandem domains and therefore underestimates the affinity of PIK3R1 for wild-type IGF1R.
Cancer network model enriches for causal cancer genes
Cancer cells typically contain many mutations, a subset of which directly promote the transformed phenotype (driver mutations), making it necessary to model the net effect of multiple mutations on a network. We formally treated cancer as a stochastic sampling process in which any given genotype is realized by random draws from a pool of mutations. This simplification ignores the sequential and interdependent accrual of cancer mutations because of insufficient data on these dependences, but it can be relaxed as data become available. Probabilities for mutations can be derived empirically from unbiased whole-genome databanks such as TCGA 16 . We constructed an ensemble over all mutations and associated a perturbed PPI network with each state in this ensemble. The resulting cancer network model (MSM/N) assigned to every potential PPI a quantity, P perturb , defined as the probability that the given PPI would be disrupted or activated by a randomly drawn mutation ( Fig. 1e and Supplementary  Fig. 1 ). P perturb integrates information at the level of domains, proteins and networks to model the impact of mutations affecting multiple proteins and their disease-specific frequencies. P perturb is central to our approach and rigorously captures the concept of a mutation that is causally responsible for a qualitative change in PPI behavior. We first used MSM/P to reconstruct the human SH2-phosphoprotein network from first principles using primary sequence data on SH2 domains and 2,292 phosphoproteins, about half of which contain multiple phosphosites (Supplementary Figs. 4 and 5, and  Supplementary Table 2) . We then obtained all whole-genome tumor sequences from the Catalogue of Somatic Mutations in Cancer (COSMIC) 16 , filtered to include mutations mapping to SH2 domains and residues proximate to confirmed sites of tyrosine phosphorylation t e c h n i c a l r e p o r t s (i.e., those with two or more sources of experimental support) 22 . This yielded 807 mutations in genes encoding SH2-containing proteins and 4,648 mutations in sequences encoding phosphoproteins across 24 tissue types and 2,206 tumor samples. We pooled all mutations and used MSM/N to derive P perturb values for every PPI (Supplementary Fig. 6, Supplementary Table 3 and Supplementary  Data Sets 1-25) . The resulting tumor network exhibited strong enrichment for cancer-associated genes (Fig. 4a) . The percentage of SH2-containing proteins or phosphoproteins annotated as oncoproteins or tumor suppressors was ~23% (by TSGene 30 and allOnco) and increased somewhat (to ~25%) when we considered only mutated SH2-containing proteins or phosphoproteins listed in COSMIC. In contrast, cancer gene enrichment increased to 75% for the top 10 interactors and 43% for the top 100 when scored by P perturb (COSMIC and P perturb did not reach parity until ~10,000 PPIs were included). We conclude that COSMIC mutations with high P perturb values are strongly associated with cancer-relevant genes.
Idiosyncratic mutations rewire SH2 signaling networks
Of 5,455 COSMIC mutations that occurred in SH2 proteins or phosphoproteins, 4,254 (78%) were idiosyncratic, occurring in only a single sample. However, we found that idiosyncratic mutations were as likely to rewire PPIs as recurrent mutations. Of 419 recurrent mutations, 23 (5.5%) were predicted to rewire PPIs at >33% probability and 5 (1.2%) were predicted to do so at >50% probability. Of 4,254 idiosyncratic mutations, 262 (6.2%) were predicted to rewire PPIs at >33% probability and 47 (1.1%) were predicted to do so at >50% probability. These results imply that tumor mutations should be analyzed with respect to function rather than frequency alone. MSM is one way to detect potentially functional, non-recurrent mutations. Figure 6 Kidney tumor network. MSM/N predictions of the top 20 perturbed interactions (green and yellow arrows) in kidney cancer overlaid on the wild-type SH2 phosphosignaling network (gray edges, each representing an interaction with P > 0.85 probability, as in supplementary Fig. 4 ). Networks were generated using a spring-electrical embedding in the Mathematica software package.
npg t e c h n i c a l r e p o r t s
Most cancer mutations disrupt individual PPIs
Tumorigenic mutations commonly affect enzymatic function by inactivating a tumor suppressor such as PTEN or constitutively activating an oncoprotein such as PI3 kinase 31 . Some mutations may function by selectively rewiring PPIs 6 . We therefore analyzed MSM/N tumor networks to identify mutations that selectively disrupted single highaffinity PPIs while leaving intact higher-and lower-affinity interactions mediated by the same mutated protein. We found that the majority (69%) of strong cancer mutations (P > 0.5) targeted a single PPI (Fig. 4b) . This appeared to hold true irrespective of the number of interactions mediated by the wild-type protein (ρ = 0.2 with one outlier interaction removed; Fig. 4c) . One exception was a mutation mapping to the GRAP2 SH2 domain that changed a tryptophan to a cysteine at a critical residue and was predicted to disrupt 117 of 130 interactions. Mutating a homologous tryptophan in the related GRB2 protein has been shown to similarly abolish its ability to bind phosphotyrosine peptides 32 .
We also observed a difference in the predicted effect of cancer mutations on SH2-containing proteins and phosphoproteins (Fig. 4d) . The vast majority of strong mutations (95%) targeted phosphoproteins and resulted in both gain (37%) and loss (63%) of interactions. Conversely, SH2 mutations led almost universally to loss of interactions (96%). The strength of the perturbational effect also differed. It took, on average, ~100 draws from the pool of phosphoprotein mutations to disrupt an interaction but only ~10 draws from the pool of SH2 mutations. For gain-of-function mutations, it took, on average, ~250 draws for phosphoproteins and ~200 draws for SH2 proteins.
Two modes of network rewiring by cancer mutations
To identify associations between cancer tissue and changes in SH2 networks, we examined the 20 most strongly disrupted PPIs, as ranked by P perturb , across 24 cancer tissues of origin. We observed two modes of action: 'node' and 'pathway' . These modes were not mutually exclusive and occurred in combination. In node cases (for example, breast and liver cancers), one or more mutations targeted a single protein and obliterated all its interactions or resulted in a gain-of-function loss of selectivity (Fig. 5a) . This mode of disruption is analogous to enzymatic mutations and might be therapeutically addressable with drugs that target a single protein. In the pathway mode, multiple mutations disrupted PPIs forming a connected path within a network ( Figs. 5b and 6) . Random targeting of such connected paths is highly improbable, as each mutation can affect ~250,000 edges, suggesting that selection may be exerted at the level of the signaling pathway. Therapeutic intervention in such cases might require agents that restore pathway-level function. We also observed differential targeting of PPIs involving the same protein across different tissues. For example, the tumor suppressor PTEN was predicted to gain or lose distinct interactions in cancers of the large intestine, endometrium and prostate (Fig. 5c) , and the affected proteins were pertinent to the tumor type. For instance, in prostate cancer, TNS1, TNS4, BCAR1 and RAC1 regulate cellular motility and invasiveness 33, 34 and the estrogen receptor ESR1 enhances proliferation 35 .
DISCUSSION
In this report, we attempt to advance the state of the art in functional genomics by developing an analytical framework for reconstructing npg t e c h n i c a l r e p o r t s SH2-phosphotyrosine signaling networks in normal and cancer cells via MSM. MSM methodology integrates and reconciles diverse genomic, biochemical and structural data and provides insights into determinants of binding specificity and the consequences of genetic mutations on the basis of biophysical principles (Fig. 7d) . On the molecular level, we find that the majority of mutations that are consequential for PPIs map to phosphoproteins and are equally likely to result in gain or loss of interactions. Conversely, SH2 domain mutations are mostly loss of function. At the network level, cancerassociated mutations rewire SH2 networks in a bimodal fashion, coordinately rewiring connected subnetworks in one mode and disrupting the total function of individual proteins in the other mode.
To summarize the selectivity of SH2 domains, we developed a new matrix representation: position energy matrices (PEMs) (Fig. 8a,  Supplementary Table 4 and Supplementary Note). Existing positionspecific scoring matrices (PSSMs) describe determinants of binding selectivity by specifying the relative preferences for a base or amino acid at each position in the bound biomolecule. In contrast, PEMs describe per-residue interaction energies using a scale that is universal across SH2 domains and residue positions (Fig. 8c) . This makes it possible to compare absolute preferences between peptide positions and capture selectivity effects that are obscured by PSSMs (Fig. 8a,b) . The PEM representation also makes clear that residue-specific negative interaction energies (those lying below the horizontal lines in Fig. 8a,b) have an important role in binding selectivity. By mapping the positionspecific MSM/D energies onto the three-dimensional structure of the SH2-phosphotyrosine binding interface (Fig. 8d) , we find that positive and negative energetic hotspots lie primarily in the peptidebinding pocket, showing that MSM/D captures the physicochemical basis of protein-peptide interaction.
Because it is probabilistic, MSM/D can estimate the proportions of false positives and false negatives in experiments (Fig. 7a ). An interaction deemed to be an experimental negative but that is assigned a 90% probability by MSM/D has only a 10% probability of being an experimental true negative and a model false positive. Using a sensitivity threshold at which MSM/D is expected to predict as many new interactions (true positives) as it loses (false negatives), MSM/D eliminates ~7 times more false positives than it adds (Fig. 7b) ; at a sensitivity threshold at which MSM/D is expected to add the same number of false positives as it eliminates, MSM/D discovers ~5 times more true positives than it loses. These results suggest a role for MSM in pruning large-scale data as a means to increase quality, sensitivity and concordance across assays (Fig. 7c) . By analogy, the introduction of Phred quality scores for DNA sequencing was critical in reducing error and increasing throughput in genomics 36 . Data pruning can also be used in an iterative approach involving model training on data and data refinement using a model. More generally, we propose that precise statistical modeling is a superior approach to reconcile irreproducible and discordant data in biomedicine 37 than simple repetition.
The MSM framework is applicable to any PID for which interaction and structural data are available (for example, PTB, SH3 and PDZ domains), including DNA-binding protein domains. Certain PIDs (for example, SH3 domains) will present additional difficulties because they lack the absolute reference frame for peptide alignment provided by phosphotyrosine residues, possibly necessitating threading and structural alignment. Moreover, MSM does not currently take into account levels of protein expression or actual states of tyrosine phosphorylation in cells but can be extended to incorporate these data as they become available (for example, from quantitative Amino acids exhibiting attractive interactions lie above the dividing line, whereas amino acids involving repulsive interactions lie below, with the height of the residue corresponding to the magnitude of the interaction energy. PEMs capture the effects of negative selectivity and differential energy contributions at different residue positions. (b) The PEM for the SH2D1B domain shows that a threonine at position −2 (relative to the phosphotyrosine site) contributes less to affinity than a leucine or isoleucine at position +3. In the PSSM, the situation is reversed because the PSSM representation forces each position to contribute equally to the total probability, which causes the dominant valine at position +3 to appear more important than it is in terms of actual energetics. Negative selectivity is also readily evident using PEMs: in the case of the TXK SH2 domain, specificity involves repulsive interactions, specifically proline, asparagine and lysine residues at positions +1, +3, and −1, respectively. These effects on selectivity cannot be discerned from the corresponding PSSM. (c) Heat map of pairwise amino acid interaction energies at the SH2-phosphopeptide interface as derived from MSM/D. Instances of strong negative energies (bright pink) correspond to electrostatic repulsion (for example, arginine and lysine), whereas positive energies (bright blue) are electrostatically complementary (for example, arginine and aspartic acid) or involve buried hydrophobic amino acids (for example, leucine and leucine). 
npg t e c h n i c a l r e p o r t s mass spectrometry). The ultimate goal is to model information flow through PID networks under different physiological conditions as a means to understand normal physiology, disease-associated mutations and patient-specific phenotypic responses. Statistical mechanical ensembles such as those described here provide the conceptual framework needed to achieve these aims.
URLs. Website associated with this report, http://lincs.hms.harvard. edu/alquraishi-natgenet-2014/; supporting source code, https:// github.com/AlQuraishiLab/sh2-cancer; allOnco Genelists, http:// www.bushmanlab.org/links/genelists.
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